Kodiak Sciences' investigational treatment for eye diseases
2 AI-extracted insights from 2 sources — podcasts, YouTube channels, and X/Twitter accounts.
Not enough scored insights about KSI-501 in the last 30 days yet.
The 2 sources with the most insights about KSI-501 on Kazuha.
AI-generated insights from podcasts, YouTube videos, and X posts — ordered by most recent.
Wet AMD results supported non-inferiority and statistical equivalence to aflibercept, despite numerically lower visual-acuity gain. Potential benefit in inflammatory subgroups, particularly DME, awaits further study.
The treatment was criticized for failing to demonstrate an advantage over Eylea while requiring more frequent injections; the speaker anticipated another failure.
Wet AMD results supported non-inferiority and statistical equivalence to aflibercept, despite numerically lower visual-acuity gain. Potential benefit in inflammatory subgroups, particularly DME, awaits further study.
The treatment was criticized for failing to demonstrate an advantage over Eylea while requiring more frequent injections; the speaker anticipated another failure.
Other assets that creators frequently mention in the same content as KSI-501.
The most active sources covering KSI-501 (KSI-501) on Kazuha are @realmartinshkreli, @shkreliplanet. Kazuha aggregates AI-extracted insights from podcasts, YouTube channels, and X/Twitter accounts.
Kazuha has indexed 2 AI-extracted insights about KSI-501 (KSI-501) from 2 different sources. New insights are added whenever a covered creator publishes a new podcast episode, video, or post.
Creators covering KSI-501 (KSI-501) most frequently also discuss KOD, EYLEA, VABY, AVST, KSI-301. See the "Discussed alongside" section above for full asset pages.